Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

1051375-16-6 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Dolutegravir API CAS No.1051375-16-6
Cas No: 1051375-16-6
No Data 10 Gram 1000 Kilogram/Month Henan Surface Industry Co Ltd Contact Supplier
Cas No: 1051375-16-6
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Cas No: 1051375-16-6
No Data 10 Metric Ton 1 Metric Ton/Day Hubei Jusheng Technology Co., Ltd., Contact Supplier
High purity dolutegravir CAS:1051375-16-6
Cas No: 1051375-16-6
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
CAS 1051375-16-6 Dolutegravir
Cas No: 1051375-16-6
USD $ 10.0-10.0 / Gram 1 Gram 10 Kilogram/Day Wuhan Vanz Pharm Inc. Contact Supplier
1051375-16-6 GSK1349572
Cas No: 1051375-16-6
USD $ 2.0-2.0 / Kilogram 1 Kilogram 100 Metric Ton/Year Hebei yanxi chemical co.,LTD. Contact Supplier
GSK1349572/1051375-16-6/ with high purity 99% in stock
Cas No: 1051375-16-6
USD $ 1.0-10.0 / Gram 1 Gram 100 Gram/Day Shengda Pharmaceutical Co., Limited Contact Supplier
Cas No: 1051375-16-6
No Data 1 Kilogram 100 Kilogram/Month Henan Tianfu Chemical Co., Ltd. Contact Supplier
GSK 1349572
Cas No: 1051375-16-6
USD $ 1.0-1.5 / Gram 1 Gram 1-100 Metric Ton/Month Baowei Technology Qinhuangdao Co., Ltd Contact Supplier
CAS 1051375-16-6 Raw Material Drug Anti ADIS Dolutegravir Powder GSK1349572
Cas No: 1051375-16-6
No Data 10 Gram 10 Metric Ton/Month Hubei XinRunde Chemical Co., Ltd Contact Supplier

1051375-16-6 Usage

Anti-AIDS drugs

Dolutegravir (Tivicay) was a new kind of anti-ADIS drug that jointly developed by the British pharmaceutical giant GlaxoSmithKline (GSK) with the Japanese Shionogi Pharmaceutical Company (Shionogi).
In July 2012, the GlaxoSmithKline Pharmaceuticals and Japan's Shionogi Pharmaceutical Company announced the results of Phase III clinical trial of the new AIDS drug Dolutegravir. After 48 weeks of treatment with dolutegravir and two other older versions of the AIDS drug, 88% of the virus in vivo was successfully inhibited, while the use of Gilead Sciences (Gilead Sciences) of the three-in-one oral drug Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate), 81% of the virus in patients was inhibited, which can be seen that, the dolutegravir developed by the GlaxoSmithKline pharmaceutical companies is slightly better. According to the researchers, in a comparative trial, owing to the side effects of the drugs, 10% of the patients stopped taking the Atripla drug developed from Gilead Technologies while only 2% stopped taking GlaxoSmithKline's dolutegravir Drug, therefore, we can see that the dolutegravir drugs from GlaxoSmithKline has slightly higher safety.
On August 12, 2013, the US Food and Drug Administration (FDA) approved the use of dolutegravir for being used in previously treated or early treated HIV-1 adults and 12 years of age and above infected children of at least 40 kg.
Dolutegravir is a once-daily drug with its efficacy being comparable to Merck's HIV/AIDS drug Raltegravir (Isentress) in Phase III clinical trials. Raltegravir should be subject to daily administration twice. Both of them are inhibitors of HIV integrase. The FDA official claim that the AIDS patient should be subject to targeted treatment on a case-by-case basis. Tivicay will provide patients with new options. In a study done a year ago, 88% of patients had a significant improvement after 48 weeks of Tivicay treatment, better than the efficacy of the Gilead's Atripla. Analysts expect that Dolutegravir will become a multi-billion-dollar blockbuster drug and a strong contender for Atripla, the world's best-selling HIV drug, developed by Gilead Sciences.
Common name: Dolutegravir
Trade name: Tivicay
Alias: GSK1349572, S-349572, GSK572
Drug Company: GlaxoSmithKline
Indications: AIDS
Drug type: integrase inhibitors
Approved date: August 12, 2013 (US)
CAS Registry Number: 1051375-16-6
Chemical name: (4R, 12aS)-N-[(2, 4-difluorophenyl) methyl]-3, 4, 6, 8, 12, 12a-hexahydro-7-hydroxy-Dioxo-2H-pyrido [1 ', 2': 4,5] pyrazino [2,1-b] [1,3] oxazine-9-carboxamide
U.S. Patent No. 8,129,385
The patent expires on October 5, 2027
International patent: W02006116764
This information is compiled and edited by Xiao Nan of Chemicalbook.


Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.


Dolutegravir (GSK1349572) is a HIV integrase inhibitor with an IC50 of 2.7 nM and is moderately effective against the significant mutants Y143R, Q148K, N155H, and G140S/Q148H against Raltegravir.

Chemical Properties

White Solid


ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]ox zine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017


1.1 GHS Product identifier

Product name Dolutegravir

1.2 Other means of identification

Product number -
Other names (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1051375-16-6 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields